Official ESCRS | European Society of Cataract & Refractive Surgeons

 

Topography-guided custom ablation treatment (TCAT) for residual refractive error after keratoplasty

Search Title by author or title

Session Details

Session Title: LASIK & PRK I

Session Date/Time: Sunday 15/09/2019 | 16:30-18:00

Paper Time: 17:21

Venue: Free Paper Forum: Podium 3

First Author: : L.Idriss SAUDI ARABIA

Co Author(s): :    M. Alharbi   A. Alqarni   M. Ahad                       

Abstract Details

Purpose:

To evaluate the efficacy and safety of Topography guided Custom Ablation Treatment (TCAT) in eyes with residual refractive error after keratoplasty.

Setting:

King Khalid Eye Specialist Hospital / Riyadh / KSA

Methods:

Retrospective study of all the patients who underwent TCAT in 2017 in our hospital. All the medical charts were reviewed and those treated for post keratoplasty refractive error (Number=46) were included in the study. Some eyes had resurfacing only (stage-1 TCAT) and other eyes had correction of refractive error (stage-2 TCAT) as well. Their pre-intervention data, surgical details and refractive outcome at six months were analyzed. Improvement or stable uncorrected visual acuity (UCVA) at 6 months compared to pre- TCAT, was defined as success. Change in refractive error in each eye was also compared.

Results:

29 eyes had stage -1 TCAT, 17 had stage 1 & 2. Overall success rate was 89.1%, with 89.7% in TCAT-1 and 88.2% in TCAT-1&2. Interval between keratoplasty and TCAT a significant risk factor for success (M-W P = 0.02) was not a significant predictor. Spherical equivalent improved significantly 6 months after TCAT (P = 0.009). Among 29 eyes undergoing stage-1 TCAT, residual spherical and cylinder of <± 1D were in 9 (31%) and 2 (7%) eyes respectively. In 17 eyes of TCAT stage 2, residual spherical and cylinder of <± 1D were in (53%) and (35%) eyes respectively.

Conclusions:

Corneal resurfacing by TCAT improves the vision in eyes with residual refractive error after keratoplasty. However, residual refractive error needs additional intervention and monitoring.

Financial Disclosure:

None

Back to previous